Erratum: Drug-target residence time and its implications for lead optimization (Nature Reviews Drug Discovery (2006) vol. 5 (730-739) 10.1038/nrd2082);Drug-target residence time and its implications for lead optimization

Nature Reviews Drug Discovery

Volumn 5, Issue 9, 2006, Pages 730-739

  Copeland, Robert A ^a   Pompliano, David L ^a   Meek, Thomas D ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMPRENAVIR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; COMPACTIN; DUTASTERIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPRISTERIDE; ERLOTINIB; FIBRINOGEN RECEPTOR ANTAGONIST; FINASTERIDE; GEFITINIB; GELDANAMYCIN; IMMUCILLIN H; INDINAVIR; LAPATINIB; LOSARTAN POTASSIUM; METHOTREXATE; NELFINAVIR; OSELTAMIVIR; PROTEINASE INHIBITOR; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; RITONAVIR; ROFECOXIB; ROXIFIBAN; SAQUINAVIR; TRIMETHOPRIM; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HYPERTENSION; IC 50; IN VITRO STUDY; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TIME;

EID: 33748325882     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2281     Document Type: Erratum

References (43)

1. Ehrlich, P. Chemotherapeutics: Scientific principles, methods and results. Lancet 182, 445-451 (1913).
2. Kenakin, T. Efficacy at G-protein-coupled receptors. Nature Rev. Drug Discov. 1, 103-110 (2002).
3. Norman, A. W., Mizwicki, M. T. & Norman, D. P. G. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nature Rev. Drug Discov. 3, 27-41 (2004).
4. Swinney D. C. Biochemical mechanisms of drug action: What does it take for success? Nature Rev. Drug Discov 3, 801-808 (2004).
5. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (Wiley, New York, 2005).
6. Fersht, A. Structure and Mechanism in Protein Science p153 (Freeman, New York, 1999).
7. Maschera, B. et al. Human immunodeficiency virus: Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271, 33231-33235 (1996).
8. Shulman, C. F., Markgren, P.-O., Hämäläinen, M. & Danielson, U. H. Elucidation of HN-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. Antiviral Res. 58, 235-242 (2003).
9. Shulman, C. F., Vrang, L. & Danielson, U. H. Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data. J. Med. Chem. 47, 5953-5961 (2004).
10. Berezov, A., Zhang, H.-T., Greene, M. I. & Murali, R. Disabling Erb B receptors with rationally designed exocyclic mimetics of antibodies: Structure-function analysis. J. Med. Chem. 44, 2565-2574 (2001).
11. Wood, E. R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationship among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
12. Rusnak, D. W. et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85-94 (2004).
13. Jencks, W. P. Catalysis in Chemistry and Enzymology (McGraw-Hill, New York, 1969).
14. Liang, J., Edelsbrunner, H. & Woodward, C. Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein Sci. 7, 1884-1897 (1998).
15. Veith, M. et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224-232 (2004).
16. Kenakin, T. A Pharmacology Primer: Theory, Application and Methods p28-29 (Elsevier, New York, 2004).
17. Harris, G. S. & Kozarich, J. W. Steroid 5α-reductase inhibitors in androgen-dependent disorders. Curr. Opin. Chem. Biol. 1, 254-259 (1997).
18. Bull, H. G. et al. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: Enzyme catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. USA 118, 2359-2365 (1996).
19. Tian, G. In vivo time-dependent inhibition of human steroid 5α-reductase by finasteride. J. Pharma. Sci. 85, 106-111 (1996)
20. Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H. & Schramm, V. L. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J. Biol. Chem. 278, 31465-31468 (2003).
21. 1 receptor. Eur. J. Pharmacol. 319, 137-146 (1997).
22. Laciurcière, Y. & Asmar, R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose in truly hypertensive patients. Am. J. Hypertens. 12, 1181-1187 (1999).
23. Vanderheyden, P. M. L., Fierens, F. L. P. & Vauquelin, G. Angiotensin II type 1 receptor antagonists: Why do some of them produce insurmountable inhibition? Biochem. Pharmacol. 60, 1557-1563 (2000).
24. Abrahamsson, T., Brandt-Eliasson, U., Morsing, P. & Sjöqvist, P. O. Candesartan causes a long-lasting antagonism of the angiotensin II receptor mediated contractile effects in isolated vascular preparations: a comparison with losartan and its active metabolite (EXP 3174). Am. J. Hypertens. 11 (Suppl. 2), 36A (1998).
25. Mousa, S. A., Bozarth, J. M., Naik, U. P. & Slee, A. Platlet GPIIb/IIIa binding characteristics of small molecule RGD mimetics: Distinct binding profile for roxifiban. Br. J. Pharmacol. 133, 331-336 (2001).
26. Billheimer, J. T. et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 99, 3540-3546 (2002).
27. Seiffert, D. et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 101, 58-63 (2003).
28. 2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25, 161-166 (2000).
29. Meltzer, H. Y. Action of atypical antipsychotics (letter to the editor). Am. J. Psychiatry 159, 153-154 (2002).
30. Shim, S. S. Action of atypical antipsychotics (letter to the editor). Am. J. Psychiatry 159, 154 (2002).
31. Planells-Cases, R. et al. A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity. J. Pharmacol. Exp. Ther. 302, 163-173 (2002).
32. Lipton, S. A. & Chen, H.-S. V. Paradigm shift in NMDA receptor drug development. Expert Opin. Ther. Targets 9, 427-419 (2005).
33. Copeland, R. A. Methods for Protein Analysis: A Practical Guide to Laboratory Protocols (Chapman & Hall, New York, 1994).
34. Copeland, R. A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis 2nd edn (Wiley, New York, 2000).
35. Motulsky, H. J. & Mahan, L. C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25, 1-9 (1984).
36. Williams, J. W., Morrison, J. F. & Duggleby, R. G. Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase. Biochemistry 18, 2567-2573 (1979)
37. Darling, R. J. & Brault, P. A. Kinetic exclusion assay technology: Characterization of molecular interactions. Assay Drug Devel. Technol. 2, 647-657 (2004).
38. Cooper, M. A. Optical biosensors in drug discovery. Nature Rev. Drug Discov. 1, 515-528 (2002).
39. Gooljarsing, L. T. et al. A biochemical rationale for the anti-cancer efficacy of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl Acad. Sci. USA (in the press).
40. Chan, C.-C. et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290, 551-560 (1999).
41. Kati, W. M. et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus replication. Antimicrob. Agents Chemother. 46, 1014-1021 (2002).
42. Inada, Y., et al. Pharmacologic properties of candesartan cilexetil - possible mechanism of long-acting antihypertensive action. J. Hum. Hypertens. 13, S75-S80 (1999).
43. Maschera, B., Furfine, E. & Blair, E. D. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69, 5431-5436 (1995).